Pathogenicity evaluation of BRCA1 and BRCA2 unclassified variants identified in portuguese breast/ovarian cancer families

Journal of Molecular Diagnostics

Volumn 16, Issue 3, 2014, Pages 324-334

  Santos, Catarina ^a   Peixoto, Ana ^a   Rocha, Patrícia ^a   Pinto, Pedro ^a   Bizarro, Susana ^a   Pinheiro, Manuela ^a   Pinto, Carla ^a   Henrique, Rui ^a,b   Teixeira, Manuel R ^a,b  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DNA; RNA;

ARTICLE; BREAST CANCER; COMPUTER MODEL; CONTROLLED STUDY; EXON; FAMILY HISTORY; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; GENETIC VARIABILITY; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; INTRON; NUCLEOTIDE SEQUENCE; OVARY CANCER; PATHOGENICITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEGREGATION ANALYSIS; VARIANTS OF UNCERTAIN SIGNIFICANCE; BREAST; BREAST NEOPLASMS; COMPUTER PROGRAM; FEMALE; GENETICS; METABOLISM; OVARIAN NEOPLASMS; OVARY; PATHOLOGY; PORTUGAL; PROCEDURES; UNCERTAINTY;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST; BREAST NEOPLASMS; FEMALE; GENETIC TESTING; GENETIC VARIATION; HUMANS; OVARIAN NEOPLASMS; OVARY; PORTUGAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SOFTWARE; UNCERTAINTY;

EID: 84898799068     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmoldx.2014.01.005     Document Type: Article

References (43)

1. M.C. King, J.H. Marks, J.B. Mandell New York Breast Cancer Study Group Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2 Science 302 2003 643 646
2. M. Robson, and K. Offit Clinical practice: management of an inherited predisposition to breast cancer N Engl J Med 357 2007 154 162
3. M.A. Carvalho, F.J. Couch, and A.N. Monteiro Functional assays for BRCA1 and BRCA2 Int J Biochem Cell Biol 39 2007 298 310
4. D.J. Farrugia, M.K. Agarwal, V.S. Pankratz, A.M. Deffenbaugh, D. Pruss, C. Frye, L. Wadum, K. Johnson, J. Mentlick, S.V. Tavtigian, D.E. Goldgar, and F.J. Couch Functional assays for classification of BRCA2 variants of uncertain significance Cancer Res 68 2008 3523 3531
5. G. Chenevix-Trench, S. Healey, S. Lakhani, P. Waring, M. Cummings, R. Brinkworth, A.M. Deffenbaugh, L.A. Burbidge, D. Pruss, T. Judkins, T. Scholl, A. Bekessy, A. Marsh, P. Lovelock, M. Wong, A. Tesoriero, H. Renard, M. Southey, J.L. Hopper, K. Yannoukakos, M. Brown, D. Easton, S.V. Tavtigian, D. Goldgar, A.B. Spurdle kConFab Investigators Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance Cancer Res 66 2006 2019 2027
6. R.M. Hofstra, A.B. Spurdle, D. Eccles, W.D. Foulkes, N. de Wind, N. Hoogerbrugge, F.B. Hogervorst IARC Unclassified Genetic Variants Working Group Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance Hum Mutat 29 2008 1292 1303
7. T.I. Orban, and E. Olah Emerging roles of BRCA1 alternative splicing Mol Pathol 56 2003 191 197
8. A. Peixoto, N. Salgueiro, C. Santos, G. Varzim, P. Rocha, M.J. Soares, D. Pereira, H. Rodrigues, M.J. Bento, A. Fraguas, G. Moura, F. Regateiro, S. Castedo, and M.R. Teixeira BRCA1 and BRCA2 germline mutational spectrum and evidence for genetic anticipation in Portuguese breast/ovarian cancer families Fam Cancer 5 2006 379 387
9. A. Peixoto, C. Santos, P. Rocha, M. Pinheiro, S. Principe, D. Pereira, H. Rodrigues, F. Castro, J. Abreu, L. Gusmao, A. Amorim, and M.R. Teixeira The c.156-157insAlu BRCA2 rearrangement accounts for more than one-fourth of deleterious BRCA mutations in northern/central Portugal Breast Cancer Res Treat 114 2009 31 38
10. L. Mohammadi, M.P. Vreeswijk, R. Oldenburg, A. van den Ouweland, J.C. Oosterwijk, A.H. van der Hout, N. Hoogerbrugge, M. Ligtenberg, M.G. Ausems, R.B. van der Luijt, C.J. Dommering, J.J. Gille, S. Verhoef, F.B. Hogervorst, T.A. van Os, E. Gomez Garcia, M.J. Blok, J.T. Wijnen, Q. Helmer, P. Devilee, C.J. van Asperen, and H.C. van Houwelingen A simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants; BRCA1 and BRCA2 as an example BMC Cancer 9 2009 211
11. P.J. Smith, C. Zhang, J. Wang, S.L. Chew, M.Q. Zhang, and A.R. Krainer An increased specificity score matrix for the prediction of SF2/ASF-specific exonic splicing enhancers Hum Mol Genet 15 2006 2490 2508
12. L. Cartegni, J. Wang, Z. Zhu, M.Q. Zhang, and A.R. Krainer ESEfinder: a web resource to identify exonic splicing enhancers Nucleic Acid Res 31 2003 3568 3571
13. O. Lungu, T.C. Wright Jr., and S. Silverstein Typing of human papillomaviruses by polymerase chain reaction amplification with L1 consensus primers and RFLP analysis Mol Cell Probes 6 1992 145 152
14. T. Wagner, D. Stoppa-Lyonnet, E. Fleischmann, D. Muhr, S. Pages, T. Sandberg, V. Caux, R. Moeslinger, G. Langbauer, A. Borg, and P. Oefner Denaturing high-performance liquid chromatography detects reliably BRCA1 and BRCA2 mutations Genomics 62 1999 369 376
15. Y. Yang, S. Swaminathan, B.K. Martin, and S.K. Sharan Aberrant splicing induced by missense mutations in BRCA1: clues from a humanized mouse model Hum Mol Genet 12 2003 2121 2131
16. M.D. Speevak, S.S. Young, H. Feilotter, and P. Ainsworth Alternatively spliced, truncated human BRCA2 isoforms contain a novel coding exon Eur J Hum Genet 11 2003 951 954
17. N.G. Howlett, T. Taniguchi, S. Olson, B. Cox, Q. Waisfisz, C. De Die-Smulders, N. Persky, M. Grompe, H. Joenje, G. Pals, H. Ikeda, E.A. Fox, and A.D. D'Andrea Biallelic inactivation of BRCA2 in Fanconi anemia Science 297 2002 606 609
18. M. Zuradelli, B. Peissel, S. Manoukian, D. Zaffaroni, M. Barile, V. Pensotti, U. Cavallari, G. Masci, F. Mariette, A.C. Benski, A. Santoro, and P. Radice Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics Breast Cancer Res Treat 124 2010 251 258
19. M. Nordling, P. Karlsson, J. Wahlstrom, Y. Engwall, A. Wallgren, and T. Martinsson A large deletion disrupts the exon 3 transcription activation domain of the BRCA2 gene in a breast/ovarian cancer family Cancer Res 58 1998 1372 1375
20. A. Peixoto, C. Santos, P. Rocha, P. Pinto, S. Bizarro, and M.R. Teixeira Molecular diagnosis of the Portuguese founder mutation BRCA2 c.156-157insAlu Breast Cancer Res Treat 117 2009 215 217
21. D.J. Sanz, A. Acedo, M. Infante, M. Duran, L. Perez-Cabornero, E. Esteban-Cardenosa, E. Lastra, F. Pagani, C. Miner, and E.A. Velasco A high proportion of DNA variants of BRCA1 and BRCA2 is associated with aberrant splicing in breast/ovarian cancer patients Clin Cancer Res 16 2010 1957 1967
22. M.P. Vreeswijk, J.N. Kraan, H.M. van der Klift, G.R. Vink, C.J. Cornelisse, J.T. Wijnen, E. Bakker, C.J. van Asperen, and P. Devilee Intronic variants in BRCA1 and BRCA2 that affect RNA splicing can be reliably selected by splice-site prediction programs Hum Mutat 30 2009 107 114
23. J. Milner, F. Fuks, L. Hughes-Davies, and T. Kouzarides The BRCA2 activation domain associates with and is phosphorylated by a cellular protein kinase Oncogene 19 2000 4441 4445
24. J. Milner, B. Ponder, L. Hughes-Davies, M. Seltmann, and T. Kouzarides Transcriptional activation functions in BRCA2 Nature 386 1997 772 773
25. A.B. Spurdle, S.R. Lakhani, S. Healey, S. Parry, L.M. Da Silva, R. Brinkworth, J.L. Hopper, M.A. Brown, D. Babikyan, G. Chenevix-Trench, S.V. Tavtigian, D.E. Goldgar kConFab Investigators Clinical classification of BRCA1 and BRCA2 DNA sequence variants: the value of cytokeratin profiles and evolutionary analysis: a report from the kConFab Investigators J Clin Oncol 26 2008 1657 1663
26. O. Diez, A. Osorio, M. Duran, J.I. Martinez-Ferrandis, M. de la Hoya, R. Salazar, A. Vega, B. Campos, R. Rodriguez-Lopez, E. Velasco, J. Chaves, E. Diaz-Rubio, J. Jesus Cruz, M. Torres, E. Esteban, A. Cervantes, C. Alonso, J.M. San Roman, R. Gonzalez-Sarmiento, C. Miner, A. Carracedo, M. Eugenia Armengod, T. Caldes, J. Benitez, and M. Baiget Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects Hum Mutat 22 2003 301 312
27. M. Capanu, P. Concannon, R.W. Haile, L. Bernstein, K.E. Malone, C.F. Lynch, X. Liang, S.N. Teraoka, A.T. Diep, D.C. Thomas, J.L. Bernstein, W.S.C. Group, and C.B. Begg Assessment of rare BRCA1 and BRCA2 variants of unknown significance using hierarchical modeling Genet Epidemiol 35 2011 389 397
28. A. Meindl German Consortium for Hereditary Breast and Ovarian Cancer Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population Int J Cancer 97 2002 472 480
29. D.F. Easton, A.M. Deffenbaugh, D. Pruss, C. Frye, R.J. Wenstrup, K. Allen-Brady, S.V. Tavtigian, A.N. Monteiro, E.S. Iversen, F.J. Couch, and D.E. Goldgar A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes Am J Hum Genet 81 2007 873 883
30. O. Anczukow, M. Buisson, M.J. Salles, S. Triboulet, M. Longy, R. Lidereau, O.M. Sinilnikova, and S. Mazoyer Unclassified variants identified in BRCA1 exon 11: consequences on splicing Genes Chromosomes Cancer 47 2008 418 426
31. A. Osorio, R.L. Milne, E. Honrado, A. Barroso, O. Diez, R. Salazar, M. de la Hoya, A. Vega, and J. Benitez Classification of missense variants of unknown significance in BRCA1 based on clinical and tumor information Hum Mutat 28 2007 477 485
32. S.V. Tavtigian, A.M. Deffenbaugh, L. Yin, T. Judkins, T. Scholl, P.B. Samollow, D. de Silva, A. Zharkikh, and A. Thomas Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral J Med Genet 43 2006 295 305
33. M. Santarosa, A. Viel, and M. Boiocchi Splice variant lacking the transactivation domain of the BRCA2 gene and mutations in the splice acceptor site of intron 2 Genes Chromosomes Cancer 26 1999 381 382
34. J.C. Thery, S. Krieger, P. Gaildrat, F. Revillion, M.P. Buisine, A. Killian, C. Duponchel, A. Rousselin, D. Vaur, J.P. Peyrat, P. Berthet, T. Frebourg, A. Martins, A. Hardouin, and M. Tosi Contribution of bioinformatics predictions and functional splicing assays to the interpretation of unclassified variants of the BRCA genes Eur J Hum Genet 19 2011 1052 1058
35. G. Giannini, C. Capalbo, E. Ristori, E. Ricevuto, T. Sidoni, A. Buffone, E. Cortesi, P. Marchetti, G. Scambia, S. Tomao, C. Rinaldi, M. Zani, S. Ferraro, L. Frati, I. Screpanti, and A. Gulino Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families Breast Cancer Res Treat 100 2006 83 91
36. Z. Kote-Jarai, D. Leongamornlert, E. Saunders, M. Tymrakiewicz, E. Castro, N. Mahmud, M. Guy, S. Edwards, L. O'Brien, E. Sawyer, A. Hall, R. Wilkinson, T. Dadaev, C. Goh, D. Easton, U. Collaborators, D. Goldgar, and R. Eeles BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients Br J Cancer 105 2011 1230 1234
37. A. Acedo, D.J. Sanz, M. Duran, M. Infante, L. Perez-Cabornero, C. Miner, and E.A. Velasco Comprehensive splicing functional analysis of DNA variants of the BRCA2 gene by hybrid minigenes Breast Cancer Res 14 2012 R87
38. M. Menendez, J. Castellsague, M. Mirete, E. Pros, L. Feliubadalo, A. Osorio, M. Calaf, E. Tornero, J. del Valle, J. Fernandez-Rodriguez, F. Quiles, M. Salinas, A. Velasco, A. Teule, J. Brunet, I. Blanco, G. Capella, and C. Lazaro Assessing the RNA effect of 26 DNA variants in the BRCA1 and BRCA2 genes Breast Cancer Res Treat 132 2012 979 992
39. E. Kwiatkowska, M. Teresiak, K.M. Lamperska, A. Karczewska, D. Breborowicz, M. Stawicka, D. Godlewski, W.J. Krzyzosiak, and A. Mackiewicz BRCA2 germline mutations in male breast cancer patients in the Polish population Hum Mutat 17 2001 73
40. F.C. Martins, S. De, V. Almendro, M. Gonen, S.Y. Park, J.L. Blum, W. Herlihy, G. Ethington, S.J. Schnitt, N. Tung, J.E. Garber, K. Fetten, F. Michor, and K. Polyak Evolutionary pathways in BRCA1-associated breast tumors Cancer Discov 2 2012 503 511
41. H. Kawai, H. Li, P. Chun, S. Avraham, and H.K. Avraham Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells Oncogene 21 2002 7730 7739
42. P.K. Lovelock, A.B. Spurdle, M.T. Mok, D.J. Farrugia, S.R. Lakhani, S. Healey, S. Arnold, D. Buchanan, I. kConFab, F.J. Couch, B.R. Henderson, D.E. Goldgar, S.V. Tavtigian, G. Chenevix-Trench, and M.A. Brown Identification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants? Breast Cancer Res 9 2007 R82
43. J.N. Glover Insights into the molecular basis of human hereditary breast cancer from studies of the BRCA1 BRCT domain Fam Cancer 5 2006 89 93